Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection

Bayerdörffer, Ekkehard; Lind, Tore; Dítě, Petr; Bardhan, Karna Dev; O'Moráin, C; Delchier, J.-C.; Spiller, Robin C.; Zanten, Sander Veldhuyzen van; Sipponen, P; Mégraud, F; Zeijlon, L.

doi:10.1097/00042737-199908002-00004

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The eradication rates achieved with this regimen were lower than those achieved with OAC, and were also lower than in studies with metronidazole‐containing regimens in other European countries 2 , . 3 , 24–29 …”

Section: Discussionmentioning

confidence: 99%

A randomized comparison of four omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with non‐ulcer dyspepsia

Laurent

Mégraud

Fléjou

et al. 2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

International guidelines for the management of Helicobacter pylori infection recommend eradication therapy with a proton pump inhibitor and two antibiotics chosen from amoxicillin, a nitroimidazole (metronidazole or tinidazole) and clarithromycin. 1 The use of such triple therapy regimens is underpinned by large randomized trials. In the metronidazole, amoxicillin, clarithromycin, H. pylori, 1-week therapy (MACH 1) study, for example, eradication rates (intention-to-treat analysis) ranged from 75.8% (95% CI, 68.3-83.3) with a twice-daily regimen consisting of omeprazole (20 mg), amoxicillin (1000 mg) and metronidazole (400 mg) given for 1 week, to 90.6% (95% CI, 85.3-95.9) with omeprazole (20 mg) plus amoxicillin and clarithromycin (500 mg each).2 Furthermore, the subsequent MACH 2 study con®rmed that such triple regimens achieve higher eradication rates, reduce the impact of primary antibiotic resistance and may decrease the risk of secondary resistance, compared with regimens consisting of two antibiotics only.3 As a result, such triple regimens now represent the`gold standard' for the eradication of H. pylori.In France, the most widely used triple regimen consists of omeprazole, amoxicillin and clarithromycin. The omeprazole, clarithromycin and metronidazole regimen

show abstract

Section: Discussionmentioning

confidence: 99%

A randomized comparison of four omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with non‐ulcer dyspepsia

Laurent

Mégraud

Fléjou

et al. 2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Data on the prevalence of primary H. pylori resistance in 1996–2000 were collected for 2003 clinical isolates, 1371of them being evaluated since 1998. Results obtained for centers in north–central (Czech Republic and Poland), northeastern (Estonia, Russia and Lithuania), south–central (Slovenia and Croatia) and southeastern (Bulgaria, Greece and Turkey) regions were compared [9–26] (pers. comm.…”

Section: Methodsmentioning

confidence: 99%

The status of antimicrobial resistance of Helicobacter pylori in eastern Europe

Boyanova

Mentis

Gubina

et al. 2002

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…In 1966, 1 was used to treat amoebic dysentery caused by Entamoeba histolytica, and in the 1970s, the treatment spectrum was expanded to include Giardia lamblia . Since its discovery, 1 has demonstrated broad spectrum activity against both Gram-positive and Gram-negative anaerobes and was included as part of a combination therapy against Helicobacter pylori to treat stomach ulcers . In the mid-1990s, 1 demonstrated antitubercular activity against anaerobic, nonreplicating Mycobacterium tuberculosis. , …”

Section: History Of Nitroimidazole Antimicrobial Agentsmentioning

confidence: 99%

“…29 Since its discovery, 1 has demonstrated broad spectrum activity against both Grampositive and Gram-negative anaerobes 22 and was included as part of a combination therapy against Helicobacter pylori to treat stomach ulcers. 30 In the mid-1990s, 1 demonstrated antitubercular activity against anaerobic, nonreplicating Mycobacterium tuberculosis. 31,32 The synthesis of 2-nitroimidazoles was finally achieved 10 years after that of 1 (Figure 2).…”

Section: History Of Nitroimidazole Antimicrobial Agentsmentioning

confidence: 99%

Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases

et al. 2017

View full text Add to dashboard Cite

Infectious diseases claim millions of lives every year, but with the advent of drug resistance, therapeutic options to treat infections are inadequate. There is now an urgent need to develop new and effective treatments. Nitroimidazoles are a class of antimicrobial drugs that have remarkable broad spectrum activity against parasites, mycobacteria, and anaerobic Gram-positive and Gram-negative bacteria. While nitroimidazoles were discovered in the 1950s, there has been renewed interest in their therapeutic potential, particularly for the treatment of parasitic infections and tuberculosis. In this review, we summarize different classes of nitroimidazoles that have been described in the literature in the past five years, from approved drugs and clinical candidates to examples undergoing preclinical or early stage development. The relatively "nonspecific" mode of action and resistance mechanisms of nitromidazoles are discussed, and contemporary strategies to facilitate nitroimidazole drug development are highlighted.

show abstract

Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection

Cited by 7 publications

References 0 publications

A randomized comparison of four omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with non‐ulcer dyspepsia

A randomized comparison of four omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with non‐ulcer dyspepsia

The status of antimicrobial resistance of Helicobacter pylori in eastern Europe

Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases

Contact Info

Product

Resources

About